Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Jun:3:42-45.
doi: 10.1016/j.pvr.2017.01.002. Epub 2017 Jan 17.

Reasons for acceptance or refusal of Human Papillomavirus Vaccine in a California pediatric practice

Brandon Brown  1 , Magi Ishak Gabra  2 , Harry Pellman  3
Affiliations

Reasons for acceptance or refusal of Human Papillomavirus Vaccine in a California pediatric practice

Brandon Brown et al. Papillomavirus Res. 2017 Jun.

Abstract

Despite the effectiveness and availability of the Human Papillomavirus (HPV) vaccine, HPV remains the most common sexually transmitted infection in the United States and has the lowest initiation rate of any routinely recommended teen vaccine. In January 2015, we surveyed parents at a Southern California pediatric private practice about reasons they accept or refuse HPV vaccine for their children. Of the 200 consecutive parents that had HPV vaccine initiation recommended for their child, 123 (61.5%) children were male and 38.5% were female. The overall age range of children was 10-17 years (median 12 years). Of the 164 (82.0%) who accepted the vaccine, a higher percentage were male (88.6% vs 71.4%, p=0.001). The most common reasons for accepting was strength of provider recommendation (84.1%) and available information (63.4%). The most common (52.8%) reason for refusing was wanting to learn more about the vaccine. These results further support the importance of both the strength of physician recommendation and improving public education about the vaccine.

Keywords: Acceptability; HPV; HPV Vaccine; Physician Recommendation.

PubMed Disclaimer

References

    1. Satterwhite C.L., Torrone E., Meites E., Dunne E.F., Mahajan R., Ocfemia M.C. Sexually transmitted infections among US women and men: prevalence and incidence estimates, 2008. Sex Transm. Dis. 2013;40(3):187–193. - PubMed
    1. de Sanjose S., Quint W.G., Alemany L., Geraets D.T., Klaustermeier J.E., Lloveras B. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol. 2010;11(11):1048–1056. - PubMed
    1. Lacey C.J., Lowndes C.M., Shah K.V. Chapter 4: burden and management of non-cancerous HPV-related conditions: hpv-6/11 disease. Vaccine. 2006;24(Suppl 3):S3/35–41. - PubMed
    1. Cogliano V., Baan R., Straif K., Grosse Y., Secretan B., El Ghissassi F. Carcinogenicity of human papillomaviruses. Lancet Oncol. 2005;6(4):204. - PubMed
    1. Reagan-Steiner S., Yankey D., Jeyarajah J. immunization services division, National Center for immunization and respiratory diseases; Center for disease control and prevention (CDC). National, regional, state, and selected local area vaccination coverage among adolescents aged 13-17 years-United States, 2015. MMWR Morb. Mortal. Wkly Rep. 2016;65(33):850–858. - PubMed

LinkOut - more resources